RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Gensight Biologics - Stock

Gensight Biologics Market capitalization 2024

Gensight Biologics Market capitalization

15.56 M EUR

Ticker

SIGHT.PA

ISIN

FR0013183985

WKN

A2ANGZ

In 2024, Gensight Biologics's market cap stood at 15.56 M EUR, a -56% increase from the 35.36 M EUR market cap in the previous year.

The Gensight Biologics Market capitalization history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)NET INCOME (undefined EUR)
2026e6.1878,64-
2025e3.61134,81-
2024e2.06235,92-
20231.27383,58-
20222.58188,23-
20215.28146,13-
20204.39169,32-
20190.7694,29-
2018---
2017---
2016---
2015---
2014---
2013---

Gensight Biologics Aktienanalyse

What does Gensight Biologics do?

Gensight Biologics SA is a biotechnology company specializing in the development of gene therapies for genetically inherited eye diseases. The company is based in Paris, France, with offices in Amsterdam and New York. The company's history began in 2012 when the founder, Bernard Gilly, had the idea to develop gene therapy for liver diseases. After several years of research and development, it became clear that the company could not develop a commercially viable solution due to the complexity of liver diseases and the high treatment costs. In 2013, the company shifted its focus to the development of gene therapies for genetically inherited eye diseases. Since then, Gensight Biologics SA has conducted several studies and clinical trials and is now a leading provider in this market segment. Gensight Biologics SA's business model is based on the development of gene therapies aimed at correcting the genetic defect and repairing the corresponding cells in the eye. The gene therapy is conducted using adeno-associated viruses (AAV), which introduce a normal gene into the diseased tissue. Gensight Biologics' particular focus is on the development of gene therapies for the treatment of eye diseases, with a focus on the research and treatment of rare diseases. The company has two central product lines. Firstly, it offers gene therapies targeting genetically inherited eye diseases such as retinitis pigmentosa (RP). This disease is inherited and leads to gradual loss of vision and, in severe cases, blindness. Gene therapy aims to repair the responsible gene and improve cell function and vision. Secondly, Gensight Biologics SA offers gene therapies targeting liver diseases such as Wilson's disease and gout, where copper and uric acid, respectively, are not properly metabolized. Here, gene therapy aims to repair the corresponding gene and reduce disease-related functional impairments. Gensight Biologics SA works closely with regulatory authorities and clinical partners to ensure the safety and efficacy of their gene therapies. The therapies are currently being tested in clinical trials to assess their effectiveness and safety. Gensight Biologics SA also collaborates with some of the world's leading doctors and researchers in the field of ophthalmology. While Gensight Biologics SA's gene therapies are still in the development phase, the clinical trials have shown promising results, and the company expects their therapies to be approved soon. The company follows a well-thought-out growth model and plans to develop further products for the treatment of eye diseases in the future. Overall, Gensight Biologics SA is a biotechnology company specialized in gene therapies, with a focus on researching and treating rare eye diseases. The company presents a promising investment option due to its innovative product range, close collaboration with researchers and clinical partners, and solid growth strategy. Gensight Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Gensight Biologics's Market Capitalization

Gensight Biologics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Gensight Biologics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Gensight Biologics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Gensight Biologics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Gensight Biologics Stock

What is the current Gensight Biologics market capitalization?

The current market capitalization of Gensight Biologics is 15.56 M EUR.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Gensight Biologics.

How has the market capitalization of Gensight Biologics developed in recent years?

The market capitalization of Gensight Biologics has increased/decreased by -56% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Gensight Biologics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Gensight Biologics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Gensight Biologics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Gensight Biologics pay?

Over the past 12 months, Gensight Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gensight Biologics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Gensight Biologics?

The current dividend yield of Gensight Biologics is .

When does Gensight Biologics pay dividends?

Gensight Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gensight Biologics?

Gensight Biologics paid dividends every year for the past 0 years.

What is the dividend of Gensight Biologics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gensight Biologics located?

Gensight Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gensight Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gensight Biologics from 7/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Gensight Biologics pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Gensight Biologics in the year 2023?

In the year 2023, Gensight Biologics distributed 0 EUR as dividends.

In which currency does Gensight Biologics pay out the dividend?

The dividends of Gensight Biologics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Gensight Biologics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Gensight Biologics

Our stock analysis for Gensight Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gensight Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.